3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Nasopharyngeal Carcinoma
11
Nasopharyngeal Neoplasms
3
Lung Neoplasms
3
Leukemia, Myeloid, Acute
3
Carcinoma, Non-Small-Cell Lung
3
Rectal Neoplasms
2
Myelodysplastic Syndromes
2
Turcot syndrome
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rhabdoid Tumor
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Patient Outcome Assessment
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoma
1
Locally Advanced Malignant Neoplasm
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Hypopharyngeal Neoplasms
1
Gastrointestinal Neoplasms
1
Interventions
pembrolizumab
4
Nivolumab
3
toripalimab
2
sintilimab
2
Neoadjuvant Therapy
2
Celecoxib
2
tislelizumab
1
spartalizumab
1
relatlimab
1
regorafenib
1
fludarabine phosphate
1
fludarabine
1
durvalumab
1
denileukin diftitox
1
danvatirsen
1
camrelizumab
1
avelumab
1
atezolizumab
1
XELOX
1
Taxes
1
Surgical Procedures, Operative
1
Radiation Dose Hypofractionation
1
Paclitaxel
1
Megestrol Acetate
1
Medroxyprogesterone Acetate
1
Ipilimumab
1
Induction Chemotherapy
1
Immunotherapy
1
Immunoglobulin G
1
Immune Checkpoint Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Turcot syndrome
×
Induction Chemotherapy
×
Clear all
NCT07259473
2026-01-07
Pre-CATALIS
Shanghai Zhongshan Hospital
Phase 2
Not yet recruiting
15 enrolled